2 assets in Sweat Gland Cancer

Therapeutic assets addressing Sweat Gland Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Sweat Gland Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Sweat Gland Cancer	National Cancer Institute (NCI)	P2	CCC (53)